Ipamorelin
Reported benefits and downsides
Each item is tagged with the kind of evidence behind it and a strength dial. Read the dial first, the claim second. How we grade evidence strength.
Reported benefits
- Selective growth-hormone release in preclinical workAnimalModerate evidence
Stimulates GH release without meaningfully elevating cortisol or prolactin, distinguishing it from older GH-releasing peptides.
- Short, stable structureMechanismModerate evidence
The pentapeptide with Aib and D-amino acids resists rapid enzymatic breakdown, supporting clinical-feasibility studies.
- Subjective wellbeing improvementAnecdotalAnecdotal only
Community users report sleep, recovery and energy improvements; not controlled trials.
Reported downsides
- Prohibited in competitive sportRegulatoryStrong evidence
Named on the WADA Prohibited List as a growth-hormone secretagogue (section S2). Banned in and out of competition.
- No marketing authorisation anywhereRegulatoryStrong evidence
Not approved by the FDA, EMA, MHRA or any national agency we cover. Status under US compounding rules is contested and evolving.
- No regulated supplyPracticalStrong evidence
Sold as a 'research chemical'. Independent testing of online vials finds frequent purity and identity failures.
- Unknown long-term human safetyUnknownLimited evidence
Limited long-duration human data. Effects on glucose handling and other endocrine axes are not well characterised in real-world use.
Where it works, where it doesn't
Where it works
- Preclinical and early-phase research on selective growth-hormone secretagogues
Where it doesn't
- Any setting that requires regulated, pharmaceutical-grade supply (no marketing authorisation anywhere)
- Competing athletes (WADA-prohibited as a growth-hormone secretagogue, section S2)
- Pregnancy, paediatric or geriatric populations (no data)
- Decisions that need defensible human dose-response data (we do not have it yet)
Where the literature comes from
An editorial estimate of the kinds of evidence available for Ipamorelin, not just what this page cites. Peptide research is rarely RCT-heavy, so the mix matters as much as the volume.
- Preclinical / animal60%
- Mechanism / pharmacology20%
- Regulatory / agency12%
- Case reports / off-label8%
How we estimate this mix: see methodology.
History at a glance
Key moments in the Ipamorelin story, from first synthesis through today.
- 1998
First synthesis and characterisation
DiscoveryPentapeptide built from non-standard residues; characterised for selective growth-hormone-releasing activity without cortisol or prolactin spikes.
- 2000
Early-phase human pharmacokinetic studies
TrialSmall studies confirm short plasma half-life and modest GH/IGF-1 elevations in healthy volunteers.
- 2024
FDA PCAC reviews compounding nomination
RegulatoryOctober 2024 Pharmacy Compounding Advisory Committee meeting reviews ipamorelin's eligibility as a bulk drug substance under section 503A.
- 2026
Federal compounding-rule easing referenced
RegulatorySubsequent regulatory shifts referenced in PMS coverage; the practical status remains unapproved as a medicine.
What we know
Ipamorelin is a short synthetic peptide, five amino acids long, designed and characterised in the late 1990s at Novo Nordisk's Helsingør research site. It was built specifically as a selective growth-hormone secretagogue: a molecule that triggers growth-hormone release at the pituitary without the cortisol and prolactin spikes that older GH-releasing peptides produced. The selectivity story is what most online discussion of ipamorelin keeps coming back to, and it is the reason the molecule kept attracting research attention even after the original sponsor stopped pursuing it commercially.
The published human evidence is mostly pharmacokinetic, not therapeutic. Early-phase studies in healthy volunteers dosed ipamorelin subcutaneously or intravenously at single or repeated doses in the 0.5-10 µg/kg range to characterise growth-hormone and IGF-1 response. Those studies confirmed a modest, short-lived GH pulse and modest IGF-1 elevation, with the selectivity profile (low cortisol/prolactin disturbance) intact. They were not designed to demonstrate efficacy for body composition, recovery, sleep, or any other clinical endpoint, and they did not run long enough to characterise chronic-use safety.
There is no published phase-2 or phase-3 trial of ipamorelin for any indication. The compound did not progress to a full clinical-trial programme. Why not is partly commercial structure (no patent runway justifying the spend, similar to BPC-157) and partly that other growth-hormone-axis approaches, including direct recombinant human growth hormone, occupy the relevant approved-medicine space. Whatever the reasons, the practical effect is that the human-data picture for ipamorelin is genuinely thin.
The mechanism (covered in 'How it works' above) is binding the GHS-R receptor on the pituitary, which is the receptor ghrelin normally activates. Ipamorelin is a ghrelin mimetic in that sense, but a far more selective one than ghrelin itself, which is partly why the cortisol/prolactin axes are relatively undisturbed in preclinical work.
Regulatory status is consistent across our coverage area: no marketing authorisation anywhere. Not by the FDA, the EMA, the MHRA, or any national agency in the EU or EEA. Ipamorelin circulates online as a research-chemical vial 'for research use only', which is a labelling convention rather than a regulatory category that legalises human use. See the country pages at /regulation/[country]/ipamorelin for jurisdiction-specific detail.
Ipamorelin is on the WADA Prohibited List under section S2 (growth-hormone secretagogues), prohibited in and out of competition for athletes subject to the WADA Code. The grey-market supply situation is similar to BPC-157: independent testing of vials sold by online vendors finds frequent purity, identity and contamination failures, and the Practical considerations section below covers the verifiable quality signals and red flags in detail.
The US compounding picture is the most active regulatory area for ipamorelin. The FDA Pharmacy Compounding Advisory Committee reviewed ipamorelin's eligibility as a bulk drug substance for compounding under section 503A at its October 2024 meeting. Subsequent federal regulatory shifts in 2026 have been referenced in PMS coverage; the practical status remains that ipamorelin is not an approved medicine, and any compounding-rule change does not change that.
This page is educational. We do not advise on starting, stopping, dosing or sourcing ipamorelin, and we do not facilitate the sale of any peptide. Decisions about whether to consider ipamorelin belong with a clinician who knows your history. Use the Regulation and Practical sections below for the operational picture, and the source list for the primary regulatory documents.
How it works
Ipamorelin is a synthetic ghrelin mimetic (a molecule that imitates ghrelin, the hormone the stomach releases when empty that drives hunger and also stimulates growth-hormone release). It binds the GHS-R receptor (growth-hormone secretagogue receptor) on the pituitary gland and triggers a pulse of growth-hormone release. The selling point in preclinical work is its relative selectivity: it appears to stimulate growth-hormone release without meaningfully raising cortisol (the stress hormone) or prolactin (the lactation hormone), which is what some older growth-hormone-releasing peptides did. The structure is short and unusual, with several non-standard amino acids (such as Aib, alpha-aminoisobutyric acid, and D-amino acids in the mirror-image form), which is what gives it metabolic stability. Most of this characterisation comes from preclinical and early-phase research; rigorous long-term human data are not available.
Where it acts in the body
- Pituitary glandBinds the GHS-R receptor (growth-hormone secretagogue receptor) and triggers a pulse of growth-hormone release.
- LiverDownstream IGF-1 elevation via pituitary GH release; magnitude modest in published work.
- Selectivity profileStimulates GH release without meaningfully elevating cortisol or prolactin in preclinical work, distinguishing it from older GH-releasing peptides.
Safety
Ipamorelin's safety data is sparse. The published human pharmacokinetic studies from the late 1990s and early 2000s did not flag major acute toxicity at the doses tested, but those studies were short-duration PK characterisations rather than therapeutic trials, and they did not run long enough to describe a chronic-use AE profile. There is no published long-term safety dataset in humans, and the metabolic, endocrine and oncologic consequences of repeated dosing for months or years remain uncharacterised. Theoretical concerns shared with other growth-hormone-axis agents include glucose dysregulation and the IGF-1-related oncology questions that apply across this drug class. The honest answer to 'is ipamorelin safe?' is 'we have a small early-phase PK picture and almost nothing on chronic use in humans.'
Is Ipamorelin legal where you live?
All countries →| Country | Status |
|---|---|
| Denmark | Not authorised |
| Sweden | Not authorised |
| Norway | Not authorised |
| Germany | Not authorised |
| Netherlands | Not authorised |
| United Kingdom | Not authorised |
| United States | Not approved |
Practical considerations
How the literature has dosed Ipamorelin, what it costs where it's authorised, how to spot a counterfeit product, and the customs reality. We report. We do not prescribe.
Dosing & administration
No approved dosing schedule exists. Early human pharmacokinetic studies dosed subcutaneously or intravenously for characterisation, not therapy.
| Context | Range | Reference |
|---|---|---|
| Early-phase human pharmacokinetic studies | 0.5–10 µg/kg as single or repeated SC/IV doses to characterise GH and IGF-1 response | Published PK literature (Helsingør / Novo Nordisk era and later academic reports) |
| Online vendor-cited 'research doses' (contested) | ≈200–300 µg, once or twice daily SC | Not validated in controlled human work |
There is no defensible human-dose regimen for ipamorelin. Published human studies dosed for pharmacokinetic characterisation, not for therapeutic effect. Online numbers are extrapolated and not endorsed by us.
Quality verification
There is no legitimate regulated supply chain for ipamorelin anywhere we cover. The same harm-reduction caveats as BPC-157 apply: this guidance is for readers who have already obtained a product.
What legitimate products show
- Batch-specific Certificate of Analysis (COA), not a generic template
- Reverse-phase HPLC purity figure ≥98% with the chromatographic method disclosed
- Identity testing by mass spectrometry confirming the ipamorelin sequence
- Bacterial endotoxin and microbiological testing within USP limits
- An ISO 17025-accredited third-party laboratory issuing the COA
Counterfeit red flags
- Generic COAs reused across multiple products from the same vendor
- Purity figures without method disclosure
- No identity testing (vial could be pure but the wrong molecule)
- Vendor refuses to share batch-specific COAs
- Bundling with other 'research peptides' as a discounted stack
Travel & customs
Travelling across borders with ipamorelin carries the same customs risk as other unauthorised research peptides. Outcomes are inconsistent; treat any attempted travel as legally risky.
Vendor reviews launching Q3 2026
We order from vendors ourselves, send samples to an independent lab, and publish what we find, including the ones that get it wrong. Ipamorelin-specific vendor reviews will live here when the testing programme is live. Until then, please assume any online seller is unverified.
Latest updates
No recent updates logged. Regulatory and trial milestones for Ipamorelin will land here as they happen.
Frequently asked
Is ipamorelin approved as a medicine?
No, not anywhere in our coverage area. It is not approved by the FDA, EMA, MHRA, or any national agency in the EU or EEA. It is sold online as a 'research chemical' or 'not for human use' product.
Why is ipamorelin described as 'selective'?
Because it stimulates growth-hormone release at the pituitary without meaningfully elevating cortisol (the stress hormone) or prolactin (the lactation hormone) in preclinical work, distinguishing it from older growth-hormone-releasing peptides like GHRP-2 or GHRP-6 that disturbed those axes more.
What does the human evidence look like?
Thin. The published human studies are mostly short-duration pharmacokinetic characterisations from the late 1990s and early 2000s that confirmed a modest, short-lived growth-hormone pulse and IGF-1 response. There is no published phase-2 or phase-3 efficacy trial for any indication.
Is ipamorelin legal to possess?
Possession sits in a grey area across our coverage area. Ipamorelin is an unauthorised medicine, not a scheduled controlled substance, so simple possession is generally not a drug-scheduling offence. Sale and supply, including online sale to consumers, is what regulators target. See the country pages for jurisdiction-specific detail.
Why are there so few clinical trials of ipamorelin?
Mostly structural: no patent runway to justify the cost of a full trial programme, and other growth-hormone-axis approaches (including recombinant human growth hormone) occupy the relevant approved-medicine space. Plenty of compounds with interesting preclinical profiles have not progressed for similar reasons.
What is the FDA Pharmacy Compounding Advisory Committee doing about ipamorelin?
PCAC reviewed ipamorelin's eligibility as a bulk drug substance for compounding under section 503A at its October 2024 meeting. Subsequent federal regulatory shifts have been referenced through 2026. Whatever the outcome on compounding, ipamorelin is not an approved medicine until a new-drug application succeeds, which is a separate and much longer process.
Glossary
Quick definitions for the technical terms used on this page. Hover any term in the body text and most browsers show the same definition; this section is the canonical reference.
- Aib
- Alpha-aminoisobutyric acid. A non-standard amino acid that resists enzymatic breakdown. One of ipamorelin's five residues.
- D-amino acid
- A mirror-image form of a standard amino acid. Slow to break down by normal enzymes; used in ipamorelin to extend metabolic stability.
- Ghrelin
- A hormone the stomach releases when empty. Drives hunger and also stimulates growth-hormone release.
- Ghrelin mimetic
- A molecule that imitates ghrelin's effect at the GHS-R receptor.
- GHS-R receptor
- Growth-hormone secretagogue receptor. The receptor that ghrelin (and ipamorelin, which mimics ghrelin) binds to drive growth-hormone release.
- Pharmacokinetics (PK)
- How a drug moves through the body: absorption, distribution, metabolism, excretion. Early ipamorelin studies were PK characterisation, not therapy.
- Pituitary
- Gland at the base of the brain. Releases growth hormone in response to GHS-R activation.
- WADA Prohibited List
- The World Anti-Doping Agency's annual list of substances banned in sport. Ipamorelin is on section S2 (growth-hormone secretagogues).
Follow Ipamorelin updates
New trial readouts, regulatory shifts, vendor-test results: get a short email when something meaningful happens on Ipamorelin. We don't spam, sell your address, or pad the list with promotions.
We'll only email about Ipamorelin. Per-peptide alerts launch with our newsletter pipeline in Q3 2026; until then we hold your address for that list and nothing else.
In the conversation
Credentialed experts and podcasters who have covered Ipamorelin on the record. We link the original source, attribute by full name, and disclose any conflict of interest. We do not paraphrase as if it were our work.
Topol places ipamorelin in his 'Non-Approved Peptides' table and writes that 'CJC-1295 releases growth hormone, as does Ipamorelin, and these given together may have synergistic (more than additive) effects.' He flags the category-level concern that 'growth hormone related peptides (CJC-1295, Ipamorelin, and Tesamorelin) carry the potential risk of cancer.' His bottom line across the piece: 'The peptide craze is unfounded. The evidence base for use of these drugs, either for off-label indications or as non-approved drugs, is wanting.'
Read→
Tatem, a fellowship-trained men's-health urologist, argues that the FDA 'silently banned 19 peptides overnight' — referring to the 2023 Category 2 listing that included ipamorelin alongside BPC-157 and others — and frames the restriction as Big Pharma-driven suppression with 'RFK Jr. reversing it all.' We report his framing because readers will encounter it. We do not endorse it: the 2023 listing followed FDA's published safety review process, the 2024 PCAC ipamorelin meeting is the actual procedural channel for revisiting it, and 'Big Pharma is hiding this' framing collapses the distinction between safety review and commercial suppression. The episode title is the host's standard clickbait format, not Tatem's words.
Conflict of interest: Paid advisor and consultant relationships with Boston Scientific, Coloplast and Endo Pharmaceuticals; runs a men's-health clinic with commercial interest in hormone and peptide-adjacent therapies.
Listen→
Huberman names ipamorelin among 'growth hormone secretagogues that people take before sleep' and asserts that 'those are FDA approved for other things,' specifically saying ipamorelin is approved 'for increasing growth hormone for people like with um reduced stature.' This is incorrect for ipamorelin: it has no FDA approval for any indication, anywhere we cover. The claim may be a confusion with sermorelin (which has had US approvals in the growth-hormone-deficiency space) or with recombinant human growth hormone itself. We surface the statement because readers will encounter it, and correct it plainly: ipamorelin is not an approved medicine in the United States, and the FDA Pharmacy Compounding Advisory Committee specifically reviewed its eligibility for 503A compounding in October 2024.
Conflict of interest: Tier 3 reflects the goop platform context, the absence of primary-source citations, and the substantive factual error about FDA approval status that we correct above. Huberman's commercial relationships include the Momentous supplement line and a long track record of supplement-company sponsorships.
Watch→